Ivermectin + Mebendazole Show 84.4% Clinical Benefit in 197-Patient Observational Study (Anticancer Research, 2026)

Few recent papers have generated as much discussion in the repurposed-drug community as the 2026 Anticancer Research report on ivermectin combined with mebendazole. With 197 enrolled patients and a headline clinical benefit ratio above 84%, it is one of the larger observational data sets available on antiparasitic drugs in oncology. This brief walks through exactly what the study measured, what its numbers mean, and — critically — what its design does and does not allow us to conclude.

Study Design and Patient Population

The study, published in Anticancer Research (Vol. 46, No. 6, 2026; PubMed 42203321), was a prospective observational cohort conducted through a telemedicine platform. It enrolled 197 cancer patients who elected to use a compounded regimen of ivermectin 25 mg and mebendazole 250 mg. Patients spanned a range of tumor types and disease stages, and many were using the regimen alongside — not instead of — their conventional oncology treatment.

Of the 197 enrolled, 122 patients (61.9%) completed the full six-month follow-up window. The remainder were lost to follow-up, discontinued, or had incomplete data. This completion rate is important context: attrition in observational cohorts can bias results, because patients who feel worse or who progress are more likely to drop out, leaving a "healthier" group among the completers. The design was deliberately pragmatic — it captured real-world use rather than the tightly controlled conditions of a randomized trial.

Key Results: Clinical Benefit and Outcomes

The headline finding was a clinical benefit ratio (CBR) of 84.4% (95% confidence interval: 77.0–89.8%). CBR here combines patients whose disease responded to or stabilized on the regimen. Broken down, the outcomes were:

• No evidence of disease (NED): 32.8% — roughly one in three completers had no detectable disease at follow-up.
• Regression: 15.6% — measurable shrinkage of existing disease.
• Stable disease: 36.1% — no significant growth over the follow-up period.
• Progression: 15.6% — disease advanced despite the regimen.

Taken at face value these are remarkable numbers. But the single most important caveat is structural: there was no control group. Because every participant received the regimen — and many were simultaneously receiving standard-of-care treatment — the study cannot attribute these outcomes to ivermectin and mebendazole specifically. A 32.8% NED rate is impossible to interpret without knowing what the same patients would have achieved on their conventional therapy alone.

Safety Profile and Adherence

On tolerability, the regimen performed well in this cohort. Adherence was high: 86.9% of patients completed their 90-capsule prescription, suggesting the protocol was manageable in daily life. Side effects were reported by 25.4% of patients and were predominantly mild gastrointestinal complaints — nausea, loose stools, and abdominal discomfort — consistent with the known profiles of both drugs. Notably, 93.6% of those who experienced side effects continued after a dose adjustment, indicating that adverse effects were generally manageable rather than treatment-limiting.

These figures should be read against the backdrop of ASCO's broader safety concerns. Mild GI effects in a monitored cohort do not rule out rarer or more serious toxicities — such as hepatic injury with prolonged benzimidazole exposure or neurological effects at high ivermectin doses — that a six-month observational study may be underpowered to detect.

Mechanisms of Action: How These Drugs Target Cancer

The biological rationale for combining these two antiparasitics rests on complementary mechanisms observed in preclinical models.

Mebendazole is a benzimidazole that binds tubulin and disrupts microtubule assembly. In dividing cancer cells this interferes with the mitotic spindle, causing cell-cycle arrest and apoptosis (programmed cell death). Because rapidly dividing cells are especially dependent on microtubule dynamics, the effect is somewhat selective for proliferating tumor tissue in laboratory systems.

Ivermectin appears to act through several signaling pathways implicated in cancer growth and survival. Preclinical work describes inhibition of STAT3, the Wnt/β-catenin pathway, and the AKT/mTOR axis, along with effects on cancer stem cells — the subpopulation thought to drive recurrence and resistance. The theoretical appeal of pairing the two is that they attack tumor biology from different angles, which could, in principle, reduce the chance of escape through a single resistance mechanism.

It is essential to stress that these mechanisms are established in cell and animal models. Demonstrating a mechanism in a dish is a necessary but not sufficient condition for clinical benefit; the human body's pharmacokinetics, immune context, and tumor heterogeneity frequently blunt effects that looked decisive in vitro.

Limitations and What Comes Next

The authors of the AR 2026 study are candid about its constraints, and any responsible reading must foreground them. The design is observational with no control group, so causation cannot be inferred. Outcomes relied in part on self-reported data. The cohort was self-selected, introducing selection bias toward motivated patients, many receiving concurrent standard therapy. Follow-up was incomplete, raising the possibility of attrition bias. For all these reasons, the study is best described as hypothesis-generating.

The logical next step — and the one both the authors and mainstream oncology point toward — is a randomized controlled trial that compares the regimen against standard care or placebo under blinded, monitored conditions. Only that design can convert an intriguing signal into reliable evidence. Until then, the study's value lies in motivating rigorous research, not in guiding self-treatment.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Prospective observational cohort study of compounded ivermectin + mebendazole in 197 cancer patients. Anticancer Research, Vol. 46, No. 6, 2026, pp. 3243+. Link (PubMed 42203321).
2. American Society of Clinical Oncology. "Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment." ASCO Connection, May 2026. Link
3. STAT News. "The National Cancer Institute is studying ivermectin as a cancer treatment." February 10, 2026. Link

Medical Disclaimer

This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.